Portal de investigación
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Nieto Benito LM
- Carretero G
- Rivera-Díaz R
- Carrascosa JM
- Daudén E
- de la Cueva P
- Herrera-Acosta E
- Baniandrés-Rodríguez O
- Lopez-Estebaranz JL
- Belinchón I
- Riera-Monroig J
- Ferrán M
- Gómez-García FJ
- Mateu A
- Rodríguez L
- Vilar-Alejo J
- García-Donoso C
- Ballescá F
- Velasco LM
- Herrera-Ceballos E
- Ruiz-Genao DP
- Descalzo MA
- García-Doval I
- el grupo de estudio BIOBADADERM
Grupos
Abstract
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. They had mean age of 16.1 years on starting treatment. When the registry was started, they had a Psoriasis Area and Severity Index of 9.4 and 67% were being treated with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs.
Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0001-7310, 1578-2190
- Tipo:
- Case Reports
- Páginas:
- 401-406
- PubMed:
- 35428502
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,279 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Actas Dermo-Sifiliograficas ELSEVIER ESPANA
Documentos
- No hay documentos
Filiaciones
Keywords
- BIOBADADERM; Childhood; Infancia; Psoriasis; Registries; Registros
Cita
Nieto LM,Carretero G,Rivera R,Carrascosa JM,Daudén E,de la Cueva P,Sahuquillo A,Herrera E,Baniandrés O,Lopez JL,Belinchón I,Riera J,Ferrán M,Gómez FJ,Mateu A,Rodríguez L,Vilar J,García C,Ballescá F,Velasco LM,Botella R,Herrera E,Ruiz DP,Descalzo MA,García I,el grupo B. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. Actas Dermo-Sifiliogr. 2022. 113(4):p. 401-406. IF:3,200.